Q-omics provides the consensus-scored MYO3B profile across patient tissues and cancer cell-line models. MYO3B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MYO3B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MYO3B RNA expression shows 13,890 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where MYO3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO3B survival associations across molecular data types. MYO3B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO3B RNA expression–survival associations across cancer types. High MYO3B expression shows unfavorable associations in KIRP, CESC, PAAD and LIHC, but favorable associations in UCS and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MYO3B RNA expression.
This table summarizes MYO3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYO3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO3B shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in HNSC, LUAD and THCA. The KIRC box plot shows higher MYO3B RNA expression in normal versus tumor tissue (log2 FC = −3.436, t-test p < 0.001).
This table shows molecular features associated with MYO3B in patient tissues and cancer cell lines. In patient samples, MYO3B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
